Enlarge / MDMA pills up close.Getty | Universal History Archive
After a remarkably sensational regulatory drug review, advisers for the Food and Drug Administration on Tuesday voted overwhelmingly against approving midomafetamine (MDMA, aka ecstasy or molly) as part of therapy for post-traumatic stress disorder.
In a response to the question, “Do the available data show that the drug is effective in patients with posttraumatic stress disorder?” advisers voted 9 “no” to 2 “yes” against MDMA. In response to the second question, “Do the benefits of midomafetamine with FDA’s proposed risk
→ Continue reading at Ars Technica